^
    Back
    Association details:
    Biomarker:RAD51 underexpression
    Cancer:Triple Negative Breast Cancer
    Drug:carboplatin (Tubulin polymerization promoter) +
    paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) +
    doxorubicin hydrochloride (Topoisomerase II inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Ann Oncol
    Title:

    Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial

    Published date:
    09/11/2021
    Excerpt:
    Patients with RAD51-low tumors benefited from PMCb (pCR 66% versus 33%, OR 3.96, 1.56-10.05, P = 0.004; interaction test P = 0.02)....RAD51 independently predicts clinical benefit from adding Cb to NACT in TNBC.
    DOI:
    10.1016/j.annonc.2021.09.003